Background The apparent diffusion coefficient (ADC) is a commonly used quantitative diffusion-weighted (DW) imaging marker in breast lesion assessment; however, reported ADC values to distinguish malignant and benign lesions show wide variability. Purpose To investigate the diagnostic performance of a tissue signature index (S-index) as a model-free diffusion marker to differentiate malignant and benign breast lesions. Materials and Methods This was a single-institution retrospective study of patients who underwent breast MRI from April 2017 to September 2018. Dynamic contrast-enhanced (DCE) MRI and DW imaging were performed with a 3-T MRI system. For DW imaging, three b values (0, 200, and 1500 sec/mm2) were used for Breast Imaging Reporting and Data Systems (BI-RADS) scoring and to calculate the S-index and a shifted ADC. The diagnostic performances of S-index, shifted ADC, and BI-RADS scoring were evaluated by using receiver operating coefficient analysis. Results The study involved 99 women (mean age, 54 years ± 14 [standard deviation]) with 69 malignant and 38 benign lesions. The S-index was higher for malignant lesions (mean, 75.9 ± 17.4) than for benign lesions (mean, 31.6 ± 21.0; P < .001). Overall diagnostic performance was identical for S-index and shifted ADC (area under the receiver operating characteristic curve [AUC], 0.95; 95% confidence interval [CI]: 0.91, 0.99) and slightly higher than for BI-RADS (AUC, 0.91; 95% CI: 0.87, 0.96; P = .22). The AUC of S-index combined with BI-RADS reached 0.98 (95% CI: 0.96, 1.00), higher than for BI-RADS alone (P < .001), yielding high sensitivity (65 of 69 [94%]; 95% CI: 85%, 98%) and specificity (36 of 38 [95%]; 95% CI: 81%, 99%). Significant differences were identified with the S-index for progesterone receptor and human epidermal growth factor receptor type 2 status (P = .003 and P < .001, respectively). Conclusion The signature index has the potential to enable classification of breast lesion types with high accuracy, especially in combination with dynamic contrast-enhanced MRI and correlates with histologic prognostic factors in invasive breast cancer.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: